Sugi Predict

Sugi Predict / Compounds / SCHEMBL498294

SCHEMBL498294

SCHEMBL498294

CN(C)[C@@](C)(Cc1ccccc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CYP3A4 P08684 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ CYP2C19 P33261 2/20 0.45
▸ CYP2D6 P10635 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ SCN1A P35498 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ SCN2A Q99250 1/20 0.45
▸ SCN3A Q9NY46 1/20 0.45
▸ SLC6A2 P23975 1/20 0.45
▸ TAAR1 Q96RJ0 1/20 0.45
▸ RIPK1 Q13546 1/20 0.45
▸ PPARG P37231 1/20 0.44
▸ PPARA Q07869 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31212623 1.00 HIF1A (0.50) HIF1ASMN1; SMN2CYP3A4LMNACYP2C19
SCHEMBL28140995 1.00 HIF1A (0.50) HIF1ASMN1; SMN2CYP3A4LMNACYP2C19
SCHEMBL6725266 0.85 BLM (0.59) CYP3A4MEN1ALOX15TSHRKMT2A
SCHEMBL6674277 0.85 BLM (0.59) CYP3A4MEN1ALOX15TSHRKMT2A
SCHEMBL5031234 0.85 HIF1A (0.50) HIF1ASMN1; SMN2CYP3A4LMNACYP2C19
SCHEMBL27945054 0.85 HIF1A (0.50) HIF1ASMN1; SMN2CYP3A4LMNACYP2C19
SCHEMBL8899299 0.84 KMT2A (0.42) HIF1ASMN1; SMN2CYP3A4LMNACYP2C19
SCHEMBL3955413 0.84 HIF1A (0.46) HIF1ASMN1; SMN2CYP3A4LMNACYP2C19
SCHEMBL9839841 0.83 HIF1A (0.53) HIF1ASMN1; SMN2CYP3A4LMNACYP2C19
SCHEMBL27305322 0.82 HIF1A (0.49) HIF1ASMN1; SMN2CYP3A4LMNACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9333212-B2 Proteasome inhibitors as ovoprotective agents to shield the ovary from chemotherapy toxicity WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2016-05-10 — — US claimed
US-20140315859-A1 Proteasome Inhibitors as Ovoprotective Agents to Shield the Ovary from Chemotherapy Toxicity WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-10-23 — — US claimed
US-20260137717-A1 TREATMENT FOR GINGIVITIS THE UNIVERSITY OF MELBOURNE (AU) 2026-05-21 — — US disclosed
US-20260115109-A1 STABILIZED STANNOUS COMPOSITIONS THE UNIVERSITY OF MELBOURNE (AU) 2026-04-30 — — US disclosed
US-12569417-B2 Compositions and methods for promoting mineralization THE UNIVERSITY OF MELBOURNE (AU) 2026-03-10 — — US disclosed
US-12551417-B2 Stabilized stannous compositions THE UNIVERSITY OF MELBOURNE (AU) 2026-02-17 — — US disclosed
US-12303548-B2 Complexes for treating sensitivity THE UNIVERSITY OF MELBOURNE (AU) 2025-05-20 — — US disclosed
US-20250152482-A1 STABILIZED STANNOUS COMPOSITIONS THE UNIVERSITY OF MELBOURNE (AU) 2025-05-15 — — US disclosed
WO-2025097213-A1 COMPOSITIONS AND METHODS FOR TREATING HALITOSIS THE UNIVERSITY OF MELBOURNE (AU) 2025-05-15 — — WO disclosed
US-20250152666-A1 COMPLEXES FOR TREATING SENSITIVITY THE UNIVERSITY OF MELBOURNE (AU) 2025-05-15 — — US disclosed
US-12239723-B2 Stabilized stannous compositions THE UNIVERSITY OF MELBOURNE (AU) 2025-03-04 — — US disclosed
EP-1105475-A1 TISSUE FACTOR PROTEIN VARIANTS WITH INCREASED AFFINITY FOR COAGULATION FACTOR FVII/FVIIA Genentech, Inc. (US) 2001-06-13 — — EP disclosed
WO-2001010892-A2 PEPTIDE ANTAGONISTS OF FACTOR VIIA GENENTECH, INC. (US) 2001-02-15 — — WO disclosed
WO-2001001749-A2 FVIIa ANTAGONISTS GENENTECH, INC. (US) 2001-01-11 — — WO disclosed
WO-2000078801-A2 INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES GENENTECH, INC. (US) 2000-12-28 — — WO disclosed
WO-2000068363-A2 ELASTASE VARIANTS AND SUBSTRATES GENENTECH, INC. (US) 2000-11-16 — — WO disclosed
US-6028055-A USE IN TREATMENT OR PROPHYLAXIS OF VARIOUS PATHOLOGICAL CONDITIONS ASSOCIATED WITH WATER OR ELECTROLYTE IMBALANCE GENETECH, INC. (US) 2000-02-22 — — US disclosed
WO-2000004148-A1 TISSUE FACTOR PROTEIN VARIANTS WITH INCREASED AFFINITY FOR COAGULATION FACTOR FVII/FVIIA GENENTECH, INC. (US) 2000-01-27 — — WO disclosed
EP-0939770-A1 RECEPTOR SPECIFIC BRAIN NATRIURETIC PEPTIDE (BNP) Genentech, Inc. (US) 1999-09-08 — — EP disclosed
WO-1998017690-A1 RECEPTOR SPECIFIC BRAIN NATRIURETIC PEPTIDE (BNP) GENENTECH, INC. (US) 1998-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137717-A1 TREATMENT FOR GINGIVITIS ACP3, FIBP, FGF23 HIF1A 2113/4885SMN1; SMN2 4527/4885CYP3A4 3528/4885
US-20260115109-A1 STABILIZED STANNOUS COMPOSITIONS CHERP, FIBP, ACP3 HIF1A 3992/4885SMN1; SMN2 1818/4885CYP3A4 4634/4885
US-12551417-B2 Stabilized stannous compositions CHERP, CA3, CA2 HIF1A 3669/4885SMN1; SMN2 1368/4885CYP3A4 4718/4885
US-12569417-B2 Compositions and methods for promoting mineralization CA3, FIBP, ACP3 HIF1A 1433/4885SMN1; SMN2 4235/4885CYP3A4 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.